PRINCETON, N.J.–(BUSINESS WIRE)–May 3, 2021–
Bristol Myers Squibb (NYSE: BMY) at the moment introduced that information from a number of research throughout the corporate’s scientific program investigating mavacamten in sufferers with obstructive hypertrophic cardiomyopathy (oHCM) will likely be introduced on the upcoming American College of Cardiology’s 70 th Annual Scientific Session (ACC.21), being held nearly May 15 to May 17, 2021.
Key displays embrace:
- A late-breaking oral presentation reporting outcomes from a brand new evaluation of information from the EXPLORER-HCM Phase Three trial of mavacamten in sufferers with oHCM, which examined the influence of mavacamten on sufferers’ well being standing (signs, perform and high quality of life) as measured by the Kansas City Cardiomyopathy Questionnaire. These information will likely be introduced as a part of the Featured Clinical Research I Session within the Hot Topics Channel on Saturday, May 15 from 12:15 – 1:30 p.m. EDT.
- A moderated poster session highlighting interim outcomes from MAVA-LTE, an ongoing, dose-blinded 5-year extension examine of the EXPLORER-HCM Phase Three trial. Findings from the interim evaluation demonstrated that in sufferers with oHCM, mavacamten was effectively tolerated and confirmed sturdy enchancment in left ventricular outflow tract (LVOT) gradients, diastolic perform, N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP) and signs.
- A poster presentation of outcomes from a real-world information evaluation measuring the scientific and financial burden of oHCM within the United States, which discovered the situation is related to substantial healthcare useful resource utilization and prices.
“These data add to the growing body of evidence that further supports the goal of addressing a high unmet medical need in patients with oHCM with mavacamten as a first-in-class medicine,” mentioned Jay Edelberg, M.D., Ph.D., head, Heart Failure and Cardiomyopathy Development at Bristol Myers Squibb. “We look forward to potentially bringing this therapy to oHCM patients early next year.”
- Health Status Benefits of Mavacamten in Patients with Symptomatic Obstructive Cardiomyopathy: Results From the EXPLORER-HCM Randomized Clinical Trial
- Author: John A. Spertus
- Session 403-09 – Featured Clinical Research I
- Session Type: Late-Breaking Clinical Trials, Hot Topics Channel
- Saturday, May 15: 12:15 – 12:25 p.m. EDT
- Long-Term Safety of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy: Interim Results of the MAVA-Long Term Extension (LTE) Story
- Author: Florian Rader
- Session 1033-03 – Advances in Hypertrophic Cardiomyopathy
- Session Type: Moderated Poster Contributions, eAbstract Site
- Saturday, May 15: 12:30 – 12:40 p.m. EDT
- Clinical and Economic Burden of Obstructive Hypertrophic Cardiomyopathy within the United States
- Author: Sneha S. Jain
- Session 2192 – Heart Failure and Cardiomyopathies: Population Science 1
- Session Type: Poster Contributions, eAbstract Site
- Saturday, May 15: 2:45 – 3:30 p.m. EDT
About Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is a continual, progressive illness by which extreme contraction of the guts muscle and decreased means of the left ventricle to fill can result in the event of debilitating signs and cardiac dysfunction. HCM is estimated to have an effect on one in each 500 folks.
The most frequent reason for HCM is mutations within the coronary heart muscle proteins of the sarcomere. In both obstructive or non-obstructive HCM sufferers, exertion may end up in fatigue or shortness of breath, interfering with a affected person’s means to take part in actions of each day dwelling. HCM has additionally been related to elevated dangers of atrial fibrillation, stroke, coronary heart failure and sudden cardiac dying, with mortality amongst HCM sufferers proven to be roughly three-fold increased than the U.S. common inhabitants at related ages.
There are presently roughly 160,000 to 200,000 folks recognized with symptomatic obstructive HCM throughout the U.S. and EU, with no current efficient drug therapy choices past restricted symptomatic reduction.
Mavacamten is a possible first-in-class, oral, allosteric modulator of cardiac myosin, beneath investigation for the therapy of situations by which extreme cardiac contractility and impaired diastolic filling of the guts are the underlying trigger. Mavacamten reduces cardiac muscle contractility by inhibiting extreme myosin-actin cross-bridge formation that leads to hypercontractility, left ventricular hypertrophy and decreased compliance. In scientific and preclinical research, mavacamten has constantly decreased biomarkers of cardiac wall stress, lessened extreme cardiac contractility and elevated diastolic compliance.
About Bristol Myers Squibb
Bristol Myers Squibb is a world biopharmaceutical firm whose mission is to find, develop and ship progressive medicines that assist sufferers prevail over severe ailments. For extra details about Bristol Myers Squibb, go to us at BMS.com or observe us on LinkedIn, Twitter, YouTube, Facebook and Instagram.
Cautionary Statement Regarding Forward-Looking Statements
This press launch accommodates “forward-looking statements” inside the that means of the Private Securities Litigation Reform Act of 1995 relating to, amongst different issues, the analysis, growth and commercialization of pharmaceutical merchandise. All statements that aren’t statements of historic information are, or could also be deemed to be, forward-looking statements. Such forward-looking statements are primarily based on historic efficiency and present expectations and projections about our future monetary outcomes, objectives, plans and aims and contain inherent dangers, assumptions and uncertainties, together with inner or exterior components that would delay, divert or change any of them within the subsequent a number of years, which can be troublesome to foretell, could also be past our management and will trigger our future monetary outcomes, objectives, plans and aims to vary materially from these expressed in, or implied by, the statements. These dangers, assumptions, uncertainties and different components embrace, amongst others, the chance that future examine outcomes will likely be in keeping with the outcomes to this point, that mavacamten might not obtain regulatory approval for the indication(s) described on this launch within the presently anticipated timeline or in any respect and, if accepted, whether or not such product candidate for such indication(s) described on this launch will likely be commercially profitable. No forward-looking assertion might be assured. Forward-looking statements on this press launch ought to be evaluated along with the numerous dangers and uncertainties that have an effect on Bristol Myers Squibb’s enterprise and market, notably these recognized within the cautionary assertion and threat components dialogue in Bristol Myers Squibb’s Annual Report on Form 10-Ok for the yr ended December 31, 2020, as up to date by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-Ok and different filings with the Securities and Exchange Commission. The forward-looking statements included on this doc are made solely as of the date of this doc and besides as in any other case required by relevant legislation, Bristol Myers Squibb undertakes no obligation to publicly replace or revise any forward-looking assertion, whether or not because of new info, future occasions, modified circumstances or in any other case.
View supply model on businesswire.com:https://www.businesswire.com/news/home/20210503005455/en/
CONTACT: Bristol Myers Squibb
KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY
INDUSTRY KEYWORD: RESEARCH CLINICAL TRIALS CARDIOLOGY OTHER HEALTH BIOTECHNOLOGY GENERAL HEALTH PHARMACEUTICAL HEALTH SCIENCE OTHER SCIENCE
SOURCE: Bristol Myers Squibb
Copyright Business Wire 2021.
PUB: 05/03/2021 09:11 AM/DISC: 05/03/2021 09:11 AM
Copyright Business Wire 2021.